Radiotherapy enhances uptake and efficacy of 90Y-Cetuximab: a preclinical trial

Labeling of molecular targeted drugs with toxic effectors is long discussed in the literature as a potential method to treat solid tumors [1]. If radionuclides are used, the approach is referred to as molecular radiotherapy [2,3]. Molecular radiotherapy has the potential to destroy localized tumors and even metastases [4,5]. However, the agents show classical limitations of molecular therapeutics, especially the barriers for drug delivery [6 –8], limiting the therapeutic doses that can be delivered to solid tumors.

Source: Radiotherapy and Oncology - November 20, 2020 Category: Radiology Authors: Antje Dietrich, Michael Andreeff, Lydia Koi, Ralf Bergman, Maik Schubert, Lena Schreiner, Steffen L öck, Wiebke Sihver, Robert Freudenberg, Sandra Hering, Hans-Jürgen Pietzsch, Jörg Steinbach, Jörg Kotzerke, Michael Baumann, Mechthild Krause Tags: Original Article Source Type: research